There has been great interest in amyloid plaque-lowering antibodies for the treatment of dementia in recent years, with the FDA’s approval of aducanumab representing the first treatment to address a defining pathology of the disease. Stephen Salloway, MD, MS, of Warren Alpert Medical School of Brown University, Providence, RI, gives an overview of ongoing clinical trials in this area, including the open-label EMBARK trial (NCT04241068) of aducanumab, the Phase III TRAILBLAZER-ALZ 2 study (NCT04437511) of donanemab and the Clarity AD (NCT03887455) and AHEAD 3-45 (NCT04468659) studies of lecanemab (NCT03887455). The antibody gantenerumab, which is administered subcutaneously, is also currently undergoing testing in a Phase III clinical trial (NCT03444870). Dr Salloway expresses that experts are eager to find out the results of these trials and what they may bring to the treatment landscape. This interview took place during the Alzheimer’s Association International Conference (AAIC) 2021.
